I have been under Dr Verter's care for a couple years after a torn retina. He and his team in Westport have been rockstars! Kudos to all!!! 👏👏👏👏
Hydroxychloroquine (Plaquenil) and Retinal Toxicity
What Is Plaquenil and How Does It Affect the Retina
Understanding how hydroxychloroquine interacts with retinal tissue helps explain why long-term use requires careful monitoring and why damage can be difficult to stop once it begins.
Hydroxychloroquine is approved to treat rheumatoid arthritis, systemic lupus erythematosus, and chronic discoid lupus erythematosus in adults. It works by calming an overactive immune system, which helps reduce inflammation, joint pain, and other symptoms of autoimmune disease. Many patients take this medication for years or even decades to keep their condition under control, which is why the potential for long-term retinal effects is so important to understand.
When hydroxychloroquine is taken over a long period, it can build up in the retina. The drug binds to melanin in the retinal pigment epithelium, or RPE, which is a layer of cells that supports the light-sensitive photoreceptors responsible for vision. This binding disrupts critical retinal functions, including the recycling of vitamin A and the process by which cells break down and remove waste products. Over time, this disruption damages both the RPE and the photoreceptors above it, particularly the cone cells in the macula (the central, detail-focused area of the retina) just outside the fovea, which is the point of sharpest vision.
One of the most important features of hydroxychloroquine retinal toxicity is that damage can continue to progress even after the medication is stopped. Because the drug remains tightly bound to melanin in the RPE for an extended period, its effects on retinal tissue do not end the moment a patient discontinues it. This makes early detection especially critical, because the window to prevent significant vision loss depends on identifying changes before they reach an advanced stage.
Who Is at Risk for Plaquenil Retinal Toxicity
Certain patients face a meaningfully higher risk of developing retinal toxicity from hydroxychloroquine. Knowing these risk factors can help guide how closely and how often a patient should be monitored.
Retinal toxicity from hydroxychloroquine affects approximately 7.5 percent of long-term users, according to data reviewed by the American Academy of Ophthalmology. At recommended doses, the risk is under 1 percent within the first five years of use and under 2 percent within the first ten years. However, the risk rises to nearly 20 percent after twenty years of treatment. These figures make clear that duration of use is one of the most significant factors in determining a patient's overall risk.
The two strongest individual risk factors for developing retinal toxicity are the daily dose and the total length of time on the medication. Patients who take more than 5.0 mg per kilogram of actual body weight per day face a significantly elevated risk. Patients who have used hydroxychloroquine for more than ten years also carry a higher risk, even at standard doses. Keeping the daily dose at or below 5.0 mg per kilogram of actual body weight is one of the most effective steps a prescribing physician can take to lower the likelihood of retinal damage.
Kidney disease is a significant risk factor because the kidneys are responsible for clearing hydroxychloroquine from the body. When kidney function is reduced, the drug can accumulate to higher levels in tissues, including the retina, increasing the likelihood of toxicity. Patients with impaired kidney function should discuss more frequent monitoring with their retina specialist.
Tamoxifen citrate, a medication commonly used to treat and prevent breast cancer, substantially increases the risk of hydroxychloroquine retinal toxicity when the two drugs are taken together. Patients on both medications require especially close monitoring, and all treating physicians should be made aware of this combination.
Several other factors are associated with a higher chance of developing retinal toxicity. Patients with any of the following characteristics may need to begin screening earlier or be monitored more frequently than the standard schedule.
- A total cumulative lifetime dose of more than 1,000 grams of hydroxychloroquine
- A daily dose over 400 mg, or more than 6.5 mg per kilogram of ideal body weight in shorter patients
- Pre-existing macular or retinal disease that may lower the retina's tolerance for additional stress
Recognizing the Signs and Symptoms
One of the most challenging aspects of Plaquenil retinal toxicity is that it progresses quietly in its early stages. By the time most patients notice any change in their vision, meaningful damage has often already occurred.
In the early stages of hydroxychloroquine retinal toxicity, the vast majority of patients have no noticeable symptoms. Vision may feel entirely normal even while subtle changes are occurring in the structure and function of the retina. This is the primary reason that routine, proactive screening is necessary rather than waiting for symptoms to prompt an evaluation.
As toxicity progresses, patients may begin to notice paracentral scotomas, which are blind spots that appear near the center of the visual field but not directly in it. These blind spots can make reading difficult because letters or words may seem to disappear in the middle of a line. Some patients also notice a gradual reduction in color vision. However, most people do not become aware of these symptoms until the affected area has grown large enough to interfere noticeably with daily tasks, which typically means the damage is already at a more advanced stage.
When retinal damage continues to worsen, central and paracentral vision become increasingly compromised. Patients may struggle to read, recognize faces, or complete tasks that rely on sharp central vision. In severe cases, a pattern called bull's eye maculopathy develops on examination, which describes a ring-shaped zone of damaged retinal tissue surrounding the fovea. At this stage, vision loss is typically substantial and cannot be reversed with any currently available treatment.
How We Test for Plaquenil Retinal Toxicity
Detecting retinal toxicity from hydroxychloroquine requires specialized testing that goes beyond a routine eye exam. We use a combination of advanced imaging and functional tests to evaluate the retina in detail and identify even subtle early changes.
Every patient beginning hydroxychloroquine therapy should have a comprehensive eye examination within the first year of starting the medication. This baseline exam serves as a reference point, documenting the normal appearance and function of the retina before any potential drug-related changes occur. It also allows our specialists to identify any pre-existing macular conditions that could complicate the interpretation of future screening results.
Optical coherence tomography, or OCT, is a noninvasive imaging test that produces highly detailed, cross-sectional images of the retinal layers. It can detect thinning or structural disruption in the outer retina before any changes become visible during a standard examination. OCT has become one of the most important tools for identifying pre-symptomatic Plaquenil toxicity, and advances in OCT technology have continued to improve its sensitivity for detecting early damage.
Automated visual field testing, particularly using the Humphrey 10-2 protocol, maps the central 10 degrees of vision and can reveal paracentral scotomas before a patient becomes aware of them. This test is one of the primary screening tools recommended by the American Academy of Ophthalmology for patients on long-term hydroxychloroquine therapy. Visual field results are compared to baseline findings over time to detect meaningful changes in the pattern or extent of vision.
Fundus autofluorescence, or FAF, is an imaging technique that evaluates the health of the retinal pigment epithelium by capturing the natural fluorescence of certain molecules within retinal cells. In patients with hydroxychloroquine toxicity, FAF can reveal abnormal patterns that indicate RPE damage before those changes are apparent on a dilated exam alone. This test is often used alongside OCT and visual field testing to provide a more complete picture of retinal health.
Multifocal electroretinography, or mfERG, measures the electrical responses of small, individual areas of the retina when stimulated by light. This test can identify localized reductions in retinal function even when imaging appears normal. While not available at every eye care practice, mfERG can provide valuable additional evidence of early toxicity when results from other tests are borderline or inconclusive.
Managing Plaquenil-Related Retinal Damage
The most effective approach to Plaquenil retinal toxicity is prevention through early detection, because no treatment currently exists to undo retinal damage once it has occurred.
Retinal damage caused by hydroxychloroquine is irreversible with currently available treatments. The photoreceptor cells and RPE cells that are destroyed do not regenerate. This is why early detection through regular screening is so critical. The entire purpose of Plaquenil toxicity screening is to identify changes at the earliest possible stage, when intervention can still prevent further harm.
When screening tests reveal early signs of retinal toxicity, the most important next step is prompt communication with the prescribing physician. Discontinuing hydroxychloroquine or transitioning to an alternative medication can slow or stop the progression of retinal damage. However, because the drug persists in retinal tissue after being stopped, some additional progression may still occur in the period following discontinuation. The decision to stop the medication must weigh the risk of continued vision loss against the benefits of ongoing autoimmune disease management, and should be made collaboratively among the patient, the prescribing physician, and a retina specialist.
Patients who stop hydroxychloroquine because of early toxicity findings should continue with regular retinal examinations. The drug can remain bound in retinal tissue for a prolonged period, meaning the potential for further damage does not end immediately when the medication is stopped. Ongoing monitoring allows any continued progression to be documented and helps the care team support the patient appropriately as vision changes are tracked over time.
Screening Schedule and What to Expect at Each Visit
Knowing when to be screened and what the process involves can help reduce anxiety and make it easier to stay consistent with follow-up appointments.
The American Academy of Ophthalmology recommends a baseline eye examination within the first year of starting hydroxychloroquine. After the baseline, annual screening should begin after five years of use for patients at standard risk. Patients with additional risk factors, such as kidney disease, high dosage, or concurrent tamoxifen use, may need to begin annual screening before the five-year mark. A retina specialist can help determine the right schedule based on your individual risk profile.
A typical Plaquenil screening visit includes a dilated eye examination, OCT imaging, and automated visual field testing. Depending on your individual risk profile and prior results, fundus autofluorescence or multifocal electroretinography may also be included. The overall process is noninvasive and generally takes about one to two hours. Our specialists compare each visit's findings to your baseline and prior results to identify any meaningful changes in retinal structure or function.
When toxicity is detected before symptoms have developed, stopping the medication gives the best chance of preserving useful vision. Patients at this stage may have only subtle changes on imaging with no apparent impact on their daily activities. Even so, early detection does not guarantee that vision will remain completely stable, since some progression can still occur after the medication is discontinued. Regular follow-up after stopping the medication is just as important as the screening that led to the discovery.
If hydroxychloroquine retinal toxicity is not identified until after vision changes have already begun, the damage is more extensive and more likely to affect tasks such as reading, driving, and recognizing faces. Stopping the medication is still recommended at this stage to limit further progression, but vision that has already been lost cannot be restored. Patients with significant visual impairment may benefit from low vision rehabilitation, which focuses on maximizing remaining sight and helping people maintain independence through adaptive tools and strategies.
Steps You Can Take to Protect Your Vision
While decisions about your medication are made with your prescribing physician, there are several practical steps you can take to actively reduce your risk of developing retinal toxicity.
Staying within the dosage guidelines your prescribing physician has established is one of the most effective ways to lower your risk. Taking more than 5.0 mg per kilogram of actual body weight per day significantly increases the likelihood of retinal toxicity over time. If you are unsure whether your current dose falls within the recommended range for your body weight, ask your prescribing physician to review this with you at your next appointment.
It is also important to attend all scheduled eye screening appointments, even when your vision feels completely normal. Because early toxicity produces no noticeable symptoms, only imaging and functional testing can identify it during the stage when intervention is most effective.
Patients taking hydroxychloroquine benefit from clear communication among all members of their healthcare team. This includes the physician who prescribes the medication, your retina specialist, and any other eye care provider involved in your care. Make sure each provider knows your full medication list, including any concurrent use of tamoxifen. Sharing your screening results across your care team helps ensure that everyone is making decisions based on the same information.
- Inform your retina specialist of any kidney disease or reduced kidney function
- Share retinal screening results with your prescribing physician after each visit
- Report any new vision changes promptly, including blind spots, difficulty reading, or changes in color perception
- Confirm that your daily hydroxychloroquine dose has been calculated based on your actual body weight
Patients who experience vision loss from hydroxychloroquine toxicity have access to low vision rehabilitation services that can help them maintain independence and quality of life. A low vision specialist can evaluate remaining sight and recommend tools such as magnifying devices, high-contrast displays, large-print materials, and adjusted lighting. Many patients find that thoughtful adjustments to their environment allow them to continue most of their daily activities. While vision that has been lost cannot be restored, living well with low vision is achievable with the right support and guidance.
Frequently Asked Questions
These answers address common questions patients ask about Plaquenil retinal toxicity, with guidance to help you make informed decisions and know when to seek care.
Yes. The absence of symptoms does not mean the retina is unaffected. Early hydroxychloroquine toxicity is consistently silent, meaning structural and functional changes can be occurring in the retina while your vision feels completely normal. The entire value of the screening protocol lies in this window: catching damage before symptoms appear is when stopping or adjusting the medication can still make a real difference. By the time vision changes become noticeable, the damage is usually at a far more advanced and less manageable stage. Keeping to your screening schedule even when you feel well is the most important protective step available to you.
In some cases, the prescribing physician may consider reducing the daily dose rather than stopping the medication entirely, particularly when the autoimmune condition being treated is severe or when alternatives carry their own risks. Whether dose reduction provides meaningful protection depends on individual factors and requires close coordination between the prescribing physician and the retina specialist. It is important to understand that there is no supplement, eye drop, or procedure that can counteract the toxicity once it is in progress. Adjusting or eliminating the medication itself is the primary lever available for slowing progression, and that decision should always involve both specialists.
There is no universally agreed-upon endpoint for post-discontinuation monitoring because the amount of time the drug remains active in retinal tissue varies from person to person. In general, continued annual monitoring for at least several years after stopping is considered prudent, particularly for patients who had any abnormality on their final screening results. Your retina specialist can assess the severity and pattern of any existing changes and recommend an appropriate follow-up interval based on your specific situation. Progression does tend to slow after stopping, but it does not halt immediately and benefits from continued observation.
Visual field testing and OCT can detect different aspects of retinal damage, and they do not always change at the same rate or at the same time. A meaningful change on the Humphrey 10-2 visual field test is taken seriously even when the OCT appears normal, because functional changes in the retina can sometimes precede structural changes that are visible on imaging. In this situation, your retina specialist will typically recommend more frequent follow-up to determine whether the finding represents early toxicity or has another explanation. A single borderline result does not always confirm toxicity, but it does warrant close and consistent monitoring going forward.
Yes, and making this happen is genuinely important to your care. The physician who prescribes hydroxychloroquine is the one who can adjust or discontinue the medication if screening results show early signs of toxicity, and without current findings they may not know that a change in management is needed. After each retinal visit, ask your retina specialist to send a copy of the report to your prescribing physician, or bring the report with you to your next appointment with them. This kind of coordination between specialists is one of the most practical and effective safeguards in managing Plaquenil toxicity over the long term.
Expert Retinal Monitoring Across Connecticut
At New England Retina Associates, our fellowship-trained vitreoretinal specialists have extensive experience monitoring patients on long-term hydroxychloroquine therapy and providing early intervention when it is needed. We serve patients throughout Connecticut with advanced diagnostic technology and the clinical expertise required to detect Plaquenil retinal toxicity at its earliest and most manageable stage. If you are taking hydroxychloroquine and have not had a recent retinal screening, or if your eye care provider has referred you for a specialist evaluation, we welcome the opportunity to support your vision and your care.
30 Years of Care & Commitment
